Argentina Updates Clinical Trial Regulations

Why this is here: Argentina’s investment in clinical research has grown by 130% in recent years, now representing 42.5% of the country’s private sector spending on research and development.

In Buenos Aires, Argentina, recent regulations update clinical trial standards to align with the Council for Harmonisation’s (ICH) E6 R3 guidelines as of December 1st. The National Administration of Medicines, Food and Medical Technology (ANMAT) streamlined protocol approvals, reducing review times from 137 to 65 days between 2017 and 2022. This modernization allows for the safe integration of digital technologies and artificial intelligence into research.

Currently, investment in clinical research represents 42.5% of private sector spending on research and development nationally. This investment has grown by 130% in recent years, creating around 6,000 direct jobs. Clinical trials proceed in four phases, starting with small groups of volunteers and expanding to populations of up to 5,000 participants, ensuring rigorous safety and efficacy evaluations.

However, Argentina and other Latin American clinical sites will need compatible digital infrastructure to support the Food and Drug Administration’s new Real-Time Clinical Trials, which aim to accelerate data analysis. Sustaining this growth requires continued focus on quality, ethics, and patient-centered care.